TP53 and cancer: The anticancer screening of Oxa + TPO-NANO demonstrated that it inhibited cellular growth and produced higher degree of morphological changes and apoptotic cell death in p53 wild-type HCT116 and p53 mutant-type HT-29 cancer cells, when compared to cells treated with Oxa-NS only.